High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (107 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: hoursevidencefirst doseagepulmonary
  Phrases that lowered it: compare theto compareweeksadversecount
• Responsible party: not given (raises risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: single (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 15.6% (lowers risk) · Drug's FDA history
• Phase: 2/3 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Minimum age: not given (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Sponsor's past trials: 1 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 25161 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus NCT03701074 · started 2018 · scored riskier than 92% of active trials terminated
• No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants NCT02128191 · started 2014 · scored riskier than 28% of active trials completed
• Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants NCT05493540 · started 2021 · scored riskier than 44% of active trials completed
• An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants NCT00750581 · started 2008 · scored riskier than 15% of active trials terminated
• Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus NCT03648437 · started 2018 · scored riskier than 18% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.